Diabetes Diagnosis & Management Online 2016

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Assessment of Cardiovascular Risk in Diabetes: A Cardiologist’s Perspective

  • Compare the effectiveness of established CVD prevention treatments in T1D and T2D versus the non-diabetic at-risk population
  • Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
  • Effectively manage cardiovascular autonomic neuropathy in T2D patients

Legacy Effect, Timing and Duration of Glycemic Control: What Can We Learn From the Long-Term Cardiovascular Trials?

  • Describe the changing epidemiologic features of CVD risk factors and CVD events in diabetes
  • Synthesize the availability of clinical tests of cardiovascular trials for glycemic control

Goals for Blood Pressure and Lipids: How Did We Get There?                                

  • Discuss the strategy and rationale of the new AHA/ACC guidelines
  • Identify blood pressure treatment targets and preferred pharmacologic treatment options for patients with diabetes
  • Discuss the recent advances in the management of hyperlipidemia
  • Compare the pros and cons of follow-up measurements in the management of lipids in T2D
  • Describe the effectiveness of various classes of lipid-modifying therapies for CVD treatment and prevention in T2D

Where Does Bariatric Surgery Fit in the Treatment and Cure of Diabetes?

  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience
  • Select appropriate medical therapy options for the co-management of diabetes and obesity
  • Recognize the appropriate provocative test to evaluate hypoglycemia from bariatric surgery

Science of Autoimmune Pathogenesis of Diabetes                  

  • Discuss the new immunization recommendations for patients with diabetes

Current Status for Prevention and Early Intervention Trials in Type 1 Diabetes

  • Evaluate clinical practice guidelines for the management of diabetes and its comorbidities and predict how these may evolve in light of new data and clinical experience
  • Discuss how new clinical studies can improve their patients' health

Biology of Fetal Islet Beta-Cell Development and Feasibility of Stem Cell Therapy

  • Discuss the recent studies on islet transplantation
  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience
  • Recognize the progression of beta-cell dysfunction in the pathophysiology of T2D

Management of Diabetic Peripheral Neuropathy

  • Screen patients for early clinical signs of neuropathy
  • Utilize protective measures to prevent foot ulcers, falls, and other morbidities that are the result of diabetic neuropathy
  • Identify available interventions specific to each neurologic impairment

Kidney Disease

  • Discuss the appropriate screening for patients with nephropathy
  • Determine the best treatment options for patients with diabetic nephropathy
  • Identify pharmacologic solutions to delay progression of nephropathy

Management of Lipids in Patients with Diabetes

  • Manage hypertriglyceridemia in a diabetic patient
  • Recognize the importance of  multidisciplinary teams in the treatment of hyperlipidemia
  • Develop a treatment strategy to address steadily increasing hypertriglyceridemia associated with worsening control of diabetes
  • Treat hyperlipidemia in patients with pharmaceutical sensitivities
  • Discuss the recent advances in the management of hyperlipidemia

Technological Advances in Treatment of Type 1 Diabetes

  • Explain the role new agents have in meeting current therapeutic challenges, including individualizing care for patients
  • Compare and critique current glycemia algorithms and discuss the place for new therapies within them

Type 1 Diabetes Management in Children

  • Determine the most effect treatment strategies for managing type 2 diabetes in children  
  • Recognize patient barriers to medication adherence and suggest strategies to overcome them
  • Identify pitfalls in insulin pump therapy
  • Utilize insulin-dosing guidelines to adjust insulin regimen

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 8.25 ABIM MOC
  • 8.25 AMA PRA Category 1 Credits
  • 8.25 CME Certificate of Participation
Course opens: 
Course expires: 

Program Chairs

John L Leahy, MD; Univ of Vermont Coll of Med
Jane E B Reusch, MD; Univ of Colorado Sch of Med/Denver Veterans Affairs Med Ctr
Carol H Wysham, MD; Rockwood Clin/Univ of Washington Sch of Med


Maryam Afkarian, MD, PhD; Univ of Washington Kidney Res Inst
Harold Bays, MD; Louisville Metabolic and Atherosclerosis Res Ctr
Carla Greenbaum, MD; Benaroya Res Inst at Virginia Mason
Matthias Hebrok, PhD; Univ of California, San Francisco Diabetes Ctr
Marc Jaffe, MD; Kaiser Permanente South San Francisco Med Ctr/Univ of California, San Francisco/San Francisco Gen Hosp
Lee Kaplan, MD, PhD; Massachusetts Gen Hosp Weight Ctr
Lori Laffel, MD, MPH; Joslin Diabetes Ctr/Harvard Med Sch
Jorge Plutzky, MD; Brigham & Women's Hosp/Harvard Med Sch
Peter Reaven, MD; Phoenix Veterans Affairs Health Care Sys/Univ of Arizona/Arizona State Univ
James Russell, MBChB, MS; Univ of Maryland Sch of Med
Matthias von Herrath, MD; La Jolla Inst for Allergy & Immunology
Howard Wolpert, MD; Joslin Diabetes Ctr/Harvard Med Sch


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Harold Bays, MD: Consultant, Alnylam, Amgen, Eli Lilly, ISIS, Merck, Novartis, Regeneron, Sanofi, Takeda; Investigator, Amarin, Amgen, Ardea, Arisaph, AstraZeneca, Bristol Meyers Squibb, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Gilead, GSK, Hanmi, Hisun, Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Merck, Necktar, Novartis, NovoNordisk, Omthe; Speaker, Amarin, Amgen, Astra Zeneca, Eisai, Regeneron, Sanofi, Takeda

Carla Greenbaum, MD: Principal Investigator, Novo Nordisk

Lee Kaplan, MD, PhD: Investigator, Johnson & Johnson

Lori Laffel, MD, MPH: Scientific Board Member, Dexcom, Novo Nordisk, Roche Diagnostics, Sanofi

John Leahy, MD: Advisory Group Member, Johnson & Johnson, Merck, Novo Nordisk, Sanofi

Peter Reaven, MD: Advisory Group Member, Amgen, Sanofi

James Russell, MBChB, MS: Investigator, Department of Veterans Affairs, National Institutes of Health, Impeto Medical

Matthias von Herrath, MD: Employee, Novo Nordisk

Howard Wolpert, MD: Consultant, Insulet, Novo Nordisk; Investigator, Abbott Laboratories, Dexcom; IP and other activities, Glooko

Carol Wysham, MD: Advisory Group Member, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Sanofi; Investigator, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi; Speaker, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi

The following faculty reported no relevant financial relationships: Maryam Afkarian, MD, PhD; Matthias Hebrok, PhD; Marc Jaffe, MD; Jane Reusch, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 8.25 ABIM MOC
  • 8.25 AMA PRA Category 1 Credits
  • 8.25 CME Certificate of Participation